Ionis Pharmaceuticals Inc (IONS)
In a report issued on August 7, Gena Wang from Barclays maintained a Sell rating on Ionis Pharmaceuticals Inc, with a price target of $50. The company’s shares closed on Friday at $68.44.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 18.3% and a 50.6% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Crispr Therapeutics AG, and Eidos Therapeutics Inc.
Ionis Pharmaceuticals Inc has an analyst consensus of Hold, with a price target consensus of $67.25, which is a -1.7% downside from current levels. In a report issued on July 23, Jefferies also reiterated a Sell rating on the stock with a $19 price target.
Endo International (ENDP)
Barclays analyst Balaji Prasad maintained a Hold rating on Endo International on August 7 and set a price target of $3. The company’s shares closed on Friday at $2.44, close to its 52-week low of $2.14.
According to TipRanks.com, Prasad is a 2-star analyst with an average return of 0.1% and a 55.6% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Osmotica Pharmaceuticals Plc, and Bausch Health Companies Inc.
The word on The Street in general, suggests a Hold analyst consensus rating for Endo International with a $6.08 average price target, which is a 149.2% upside from current levels. In a report issued on July 26, Mizuho Securities also reiterated a Hold rating on the stock with a $6 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.